Bridget Martell, MA, MD is a seasoned biopharmaceutical corporate executive with high-impact, results-oriented breadth and depth with a demonstrated track record in financing, building, and leading highly successful companies. She has served in numerous C-Suite, Venture, and Independent Board roles, most recently President and Chief Executive Officer of Artizan Biosciences, Inc., a part-time Healthcare Venture Partner with AlleyCorp, an early stage venture capital company, and as an Independent Board Director of Achieve Life Sciences, Aligos Therapeutics, and POINT Biopharma (acquired by Lilly, September 2023). Under the auspice of her consulting practice, BAM Consultants LLC, Bridget has held various leadership positions in early stage to late stage public and private companies, including Chief Medical Officer of three private and two publicly traded companies as well as at RRD International, a boutique Contract Research Organization (acquired by Uniphar in 2021). She began her pharmaceutical career at Pfizer where she held leadership roles of increasing responsibility from 2005 to 2011. Bridget earned her BS in microbiology from Cornell University, her MA in molecular immunology from Boston University and her MD from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Bridget is board certified in both internal and addiction medicine.